Overview

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Status:
Enrolling by invitation
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Phase:
Phase 3
Details
Lead Sponsor:
UCB Biopharma SRL